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Abstract
Background: Barriers to depression treatment among Hispanic populations include persistent stigma, inadequate
doctor patient communication (DPC) and resultant sub-optimal use of anti-depressant medications. Stigma is
primarily perpetuated due to inadequate disease literacy and cultural factors. Common concerns about depression
treatments among Hispanics include fears about the addictive and harmful properties of antidepressants, worries
about taking too many pills, and the stigma attached to taking psychotropic medications. The current manuscript
presents the study protocol for the Depression Screening and Education: Options to Reduce Barriers to Treatment
(DESEO) study funded by the Center for Medicare and Medicaid Services (CMS) Grants to Support the Hispanic
Health Services Research Grant Program.
Methods/Design: DESEO will implement universal screening with a self-report depression screening tool
(the 9-item Patient Health Questionnaire (PHQ-9)) that is presented through a customized web application and a
Depression Education Intervention (DEI) designed to increase disease literacy, and dispel myths about depression
and its treatment among Hispanic patients thus reducing stigma and increasing treatment engagement. This
project will be conducted at one community health center whose patient population is majority Hispanic. The
target enrollment for recruitment is 350 patients over the 24-month study period. A one-group, pretest-posttest
design will be used to asses knowledge of depression and its treatment and related stigma before, immediately
after, and one month post intervention.
Discussion: Primary care settings often are the gateway to identifying undiagnosed mental health disorders,
particularly for people with comorbid physical health conditions. This study is unique in that it aims to examine
the specific role of patient education as an intervention to increase engagement in depression treatment.
By participating in the DEI, it is expected that patients will have time to understand treatment options, participate
in shared decision-making with their provider, and increase engagement in treatment of depression which might
lead to improved overall health. It is also expected that implementation of the iPad Depression Screening
application will increase provider awareness of the incidence and prevalence of depression in their own practice
and improve the performance and care the clinic provides.
Trial registration: The study was registered with: NCT02491034 July 2, 2015.
Keywords: Depression, Education, Hispanics, Stigma, Primary care, iPad screening, Fotonovela
* Correspondence: KSanchez@uta.edu
1School of Social Work, University of Texas at Arlington, 211 South Cooper
Street, Arlington, TX 76019, USA
2Department of Psychiatry, UT Southwestern Medical Center, 5323 Harry
Hines Blvd., Dallas, TX 75390-9119, USA
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.




Clinical depression is the leading cause of medical
disability, health burden, and increased medical cost in
the United States and the world, costing an estimated $
83–125 billion in the U.S. each year, and more than half
these expenses are publicly funded [1]. It is estimated
that the lifetime prevalence of a psychiatric disorder for
Hispanics residing in the United States is 28.1 % for men
and 30.2 % for women. Hispanics are more likely to
experience a psychiatric disorder if they are born in the
United States, are proficient in the English language, or
are third-generation in the United States [2]. Hispanics
have a higher prevalence of diabetes but also have
double the risk of comorbid depression than the general
population, with rates as high as 33 % [3].
For many Hispanics, response to depression treatment
may require a considerable amount of time to reach
remission, as much as two and a half years [4] Additionally,
relapse rates are high and the slow response to treatment
may explain the premature discontinuation of medication
by patients. Intractable symptoms and slow recovery leave
minority populations with a considerable disease burden
for a substantial length of time compared to non-Latino
whites [4, 5].
Low use of anti-depressant medication, poor doctor
patient communication, and persistent stigma around
issues of mental illness are key barriers to the treatment
of depression in Hispanic populations [4, 6, 7]. Hispanics
initiate anti-depressant medication treatment at a much
lower rate than whites, and are more likely to discon-
tinue their treatment for depression without consulting
their physician, in spite of being equally likely as whites
to have received a medication prescription from their
primary care provider [8]. Common concerns about
depression treatments include fears about the addictive
and harmful properties of antidepressants, worries about
taking too many pills, and the stigma attached to taking
psychotropic medications [9, 10]. Somatic presentation
of depressive symptoms, especially in the context of
comorbid illness, impedes accurate and timely detection
by primary care providers and, in settings where
systematic screening for depression is absent, barriers to
treatment are further amplified [11].
Primary care
By 2003, 54 % of people with mental health disorders
were served in primary care, without referral to specialty
mental health [12], supporting the description of
primary care as the ‘de facto’ mental health care system
[13]. Hispanics, in particular, are more likely to receive
mental health care in primary care settings [14]. Many
reasons have been cited for this trend, from lack of access
to mental health specialists, income and insurance barriers,
to the trust of the relationship with the family physician
[15, 16]. Additionally, low English proficiency is associated
with reports of poor quality of primary care, an absence of
a source of care, and a lack of continuity [17]. Other
studies conclude that treatment and linguistic barriers are
likely to be even more pronounced at the community level
for Hispanics [18–21].
Importance of screening
Self-report depression screening instruments can save
provider time, minimize stigma, and engage patients in
the identification of their symptoms of depression. Screen-
ing instruments can be powerful tools in assisting primary
care providers with detecting depression in their patient
population, diagnosing depression and monitoring treat-
ment response. These instruments can also help track a
patient’s overall depression severity as well as the specific
symptoms that are improving or not with treatment [22].
The most recent recommendations from the U.S. Prevent-
ive Services Task Force are that primary care providers
screen adult patients for depression only if systems are in
place to ensure treatment and follow-up [23].
Role of education
Management of depression among Hispanics in
community-based safety net settings is confounded by
issues of disease literacy, cultural treatment preferences
and financial barriers to care [24, 25]. The role of patient
education in management of chronic disease to increase
patient engagement and improve health outcomes has
been well established [26]. However, less is known about
patient education and its role in mental illness [27].
Depression education interventions, which focus on
symptom recognition, stress reduction techniques, and
behavioral activation to reduce barriers to treatment,
show promise [28, 29].
Educational interventions to proactively address barriers
to depression treatment for Hispanic patients have
included adapting materials for literacy and cultural
content, reimbursing patients for completing outcome
measures, and covering transportation expenses. Additional
strategies include offering the patients the opportunity to
include family members in sessions, if preferred, with a
particular focus on linking patient education to depression
self-management and socioeconomic stressors created by
their illness. Provision of patient education and homework
materials that are linguistically, idiomatically, and literacy-
level appropriate is key [30].
Aims
The current paper provides a description of the design of
DESEO: Depression Screening and Education: Options to
Reduce Barriers to Treatment. The primary aim of DESEO
is to implement a Depression Education Intervention (DEI)
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designed to increase disease literacy, and dispel myths
about depression and its treatment among Hispanic
patients thus reducing stigma and increasing treat-
ment engagement. The secondary aim of the study is
to test the feasibility of universal screening for de-
pression utilizing the 9-item Patient Health Question-
naire (PHQ-9) [31] via the iPad Depression Screening
application.
Objectives
1. To increase knowledge of depression
(signs/symptoms, causes, risk factors, treatment,
cultural beliefs, and its role in chronic disease)
among Hispanics in a primary care setting.
2. To reduce perceived cultural stigma about
depression and its treatment through a culturally
and linguistically appropriate educational
intervention.
3. To increase engagement in depression treatment
in primary care by Hispanic patients.
4. To systematically screen all adult primary care
patients with an iPad Depression Screening
application.
5. To increase provider detection of depression in
patients through the proper use and interpretation
of the PHQ-9.
Hypotheses
Our hypothesis is that the provision of depression
education to Hispanic patients in a community based
health center will lead to an increase in the understand-
ing of depression, a reduction in stigma and an increase
in patient engagement in treatment. Additionally, we
hypothesize that the implementation of the iPad Depres-
sion Screening application will increase provider aware-
ness of the incidence and prevalence of depression in
their own practice and thus improve the performance
and care the clinic provides.
Methods/Design
Setting and participants
The study will take place at one Federally Qualified Health
Center that primarily serves a Hispanic population in
north Texas and whose mission is to provide a community
medical home through accessible, compassionate and
quality health care services. The center offers a full range
of quality family-oriented comprehensive primary and
preventive services, including Family Medicine, Pediatrics,
Obstetrics/Gynecology, family planning services, prenatal
care, and health education promotion and disease pre-
vention services. In 2013, the clinic had 11,274 undu-
plicated patients and 25,362 patient visits. Of those
patients, 83 % were Hispanic. The majority did not
speak English.
The target enrollment for recruitment is 350 patients
over the 24-month study period. All adult primary care
patients at the clinic will be asked to participate in
screening for depression with the iPad Depression Screen-
ing application (universal screening). The clinic sees an
average of 450–500 unique adult patients per month (new
and/or unduplicated) or 100–125 patients per week. It is
expected that at least 10 % of the patient population will
screen positive for depression. Patients that are not
Hispanic will be ineligible for the study because the inter-
vention is culturally and linguistically adapted for a
Hispanic population. Patients who are already in treat-
ment for depression (medication and/or psychotherapy)
will also be excluded since treatment engagement is an
expected outcome. The study protocol was reviewed and
approved by the Institutional Review Board of the
University of Texas at Arlington. All patients will provide
written informed consent to participate.
Study design and intervention
This project will implement universal screening for
depression and a Depression Education Intervention
(DEI) to increase detection, diagnosis, and treatment of
depression at one community health center whose
patient population is majority Hispanic. The project will
begin with a self-report depression screening tool that is
administered to all clinic patients (universal screening)
through a customized web application using an iPad.
This iPad Depression Screening application technology
represents an innovative, evidence-based initiative that is
the first of its kind in that it aims to increase access to
depression screening for patients in primary care.
Through the use of the iPad Depression Screening
application, patients will be identified and referred to the
Depression Educator. The DEI is designed to increase
disease literacy, and dispel myths about depression and
its treatment. A one-group pretest-posttest design will
be used to asses knowledge of depression and its treat-
ment and related stigma before, immediately after, and
one month post education intervention.
Universal screening with iPad technology
The first step will involve training primary care providers
and designated clinical staff in the use and interpretation
of the PHQ-9 and the utilization of the iPad Depression
Screening application. All adult primary care patients will
be asked to complete the iPad Depression Screening
(universal screening) at the annual visit and at new/non-
acute visits. Using a brief script, medical assistants (MAs)
will give the patient the iPad during the routine intake
process (weight, blood pressure, etc.) and ask them to
complete the screening for depression. Patients can refuse
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the depression screening process with no adverse effect to
the services they receive at the clinic. The first screen in
the iPad application will be used to record consent, and
the patient will be informed that refusal to consent for
screening will have no effect on the care they receive at
the clinic. If the patient does not consent, the screening
process will be terminated and the patient will continue
with their scheduled visit.
The iPad Depression Screening application begins with
the first two screening items of the PHQ-9 (the PHQ-2).
The PHQ-2 is a validated “first-step” approach to screen
for depression, which indicates if a patient should be fur-
ther evaluated using the PHQ-9 [32]. For patients with
scores above 3 on the first two items, the application
automatically expands to the additional 7 items of the
PHQ-9. The iPad Depression Screening will be pre-
sented in English or Spanish, depending on the patient’s
preference. Once completed, an electronic notification is
generated to the Depression Educator, the patient’s pri-
mary care provider and other designated clinic staff car-
ing for the patient. Upon completion of the screening,
the application screen will lock with a message to return
the iPad to a clinic staff member.
Immediately after a patient screens positive for depres-
sion, the intake nurse will document the PHQ-9 score in
the patient’s electronic health record (EHR). A notifica-
tion will inform the provider that the patient screened
positive for depression to enable the provider to inter-
pret the depression score. Patients identified as de-
pressed by the iPad Depression Screening application
will be further assessed using the Major Depression
Diagnostic Checklist (MDDC), a clinical interview tool
used to confirm the nine criteria for depression from the
Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV) [33]. The provider will then immediately fa-
cilitate an introduction to the Depression Educator, a
practice known as a warm hand off, which establishes
rapport and instills a sense of trust in the patient. Pa-
tients who do not meet the diagnostic criteria for de-
pression will be excluded from the study. See Fig. 1 for a
summary of the study flow.
Depression Education Intervention (DEI)
Patients identified as depressed by the iPad Depression
Screening application (PHQ-9) will be referred to the
Depression Educator for potential enrollment in the
Depression Education Intervention (DEI). Patients who
screen positive for depression but previously had a diag-
nosis of depression and are in treatment, will be
excluded from enrollment in the DEI. The Depression
Educator will confirm the diagnosis of major depression
using the MDDC, if the provider has not already done
so, and that the patient is not currently in treatment for
depression or other mood disorder. The Depression
Educator will explain the current project, including the
compensation for completion of study measures at two
sessions: baseline session to consent and enroll, and after
completion of the DEI within 2 weeks. The Depression
Educator will also explain that there will be one follow-up
phone call one month after the completion of the DEI
session. The Depression Educator will attempt to build
rapport, engage the patient, and invite the patient to
participate. If the patient agrees to participate in the
DEI, s/he will be guided through the informed con-
sent process. If a patient declines participation, s/he
will receive routine care for their depression from the
clinic providers.
The Depression Educator will document the patient’s
PHQ-9 baseline score and administer the rest of the
baseline measures, which includes the Depression
Knowledge Measure (DKM) and three stigma measures
(see Table 1). All measures will be documented in an
electronic, password-protected research database. The De-
pression Educator will then schedule the patient to return
to the clinic for the DEI. The patient will be encouraged to
bring family members and loved ones to the session. The
patient should be scheduled to return for the DEI within
several days, at most within 2 weeks, of the first session.
When the patient returns for the DEI, the Depression
Educator will administer the PHQ-9 via the iPad Screen-
ing Application prior to the education intervention. The
DEI uses a unique, culturally adapted depression fotono-
vela titled “Secret Feelings” developed by Cabassa,
Molina and Baron [34]. The fotonovela is a popular
comic-book style pamphlet that portrays a dramatic
story using photographs and dialogue bubbles, which
has become an effective tool for engaging Hispanic audi-
ences and increasing knowledge about specific health
issues [35, 36]. Using the fotonovela as a tool to promote
discussion, the DEI is designed to enhance the awareness
and understanding of depression, its role in chronic
disease, its impact on Hispanic populations and the
multitude of barriers to effective treatment. The DEI will
be provided in one individual session by the Depression
Educator in the presence of support by family members
or loved ones, if desired. The DEI will be provided in
English or Spanish depending on patient preference, to
reduce stigma and enhance the comfort of patients to
ask questions and discuss fears. Upon completion of the
DEI, the patient will be asked to complete the DKM and
the three stigma measures again. The Depression
Educator will record the results of the measures and the
second PHQ-9 in the research database. See Fig. 1 for
study flow, Table 1 for summary of measures.
To determine the effectiveness of the intervention in
engaging participant’s in depression treatment, the
Depression Educator will call the patient one month
after the DEI. The Depression Educator will assess if the
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patient is currently engaged in depression treatment of
any kind (pharmacotherapy, counseling or other behav-
ioral intervention). When possible, the information will
be verified with the EHR. The Depression Educator will
also administer all measures including the PHQ-9, DKM
and three stigma measures (see Table 1).
Measures
Patient Health Questionnaire (PHQ-9)
The PHQ-9 is a self-report of frequency of symptoms
for “the last 2 weeks” on each of the nine Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV) [33]
criteria for depression, which results in a range of
Fig. 1 DESEO Participant Flow
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possible scores from 0 to 27. PHQ-9 scores of 5 – 9 repre-
sent mild depression, 10 – 14 represent moderate depres-
sion, 15 – 19 represent moderately severe depression, and
>20 represent severe depression [37]. Patients with a
PHQ-9 score ≥10 are considered to have clinically signifi-
cant depressive symptoms. Studies in primary care sam-
ples indicate the PHQ-9 to be a reliable and valid measure
of depression severity with a Cronbach’s alpha of 0.89, and
has demonstrated construct validity among African
American, Latino and non-Hispanic white populations
[38, 39]. The PHQ-9 has been translated and validated in
Spanish. The screening is designed to provide requisite
information while not overburdening patients and pro-
viders. The PHQ-9 will be administered at screening prior
to enrollment in the DEI, at the second session before the
DEI is conducted, and one-month post-DEI. See Table 1.
Depression Knowledge Measure (DKM)
The DKM [40] evaluates symptom recognition and
treatment knowledge. Symptom recognition is assessed
with a list of 10 symptoms, including 5 DSM-IV depres-
sion symptoms and 5 non-depressive symptoms: hearing
voices, sleeping too little, eating too much, being full of
energy, feeling guilty, feeling agitated, being violent, loss
of interest, having hallucinations, and feeling confident.
Respondents receive one point for each symptom that
they identify correctly as a depression symptom or not a
depression symptom. Treatment knowledge is assessed
with 7 true–false questions from the Griffiths et al. [41]
Depression Literacy Questionnaire (D-Lit) measure,
adapted for use with Hispanic populations. Respondents
receive one point for each question answered correctly.
With 10 symptom recognition items and 7 treatment
knowledge items, the DKM scores range from 0 (all
incorrect) to 17 (all correct). The measure will be
administered at baseline, after the Depression Education
Intervention (DEI), and one-month post-DEI session.
See Table 1.
Three brief stigma measures with demonstrated
validity and reliability among Spanish-speaking, Hispanic
primary care patients will be used to measure key stigma
constructs which deter treatment utilization [42]. The
three scales will be administered at baseline, after the
DEI, and one-month post-DEI, see Table 1.
Stigma Concerns about Mental Health Care (SCMHC)
The SCMHC [42] is a 3-item measure which assess stigma
related barriers to depression treatment utilization (sample
item: “I would not want to receive treatment for depression
because of being embarrassed to talk about personal
matters with others”). Response options are scored as 0
= “Disagree” and 1 = “Agree.” The SCMHC score is calcu-
lated by taking the sum of the 3 items and total score
ranges from 0 – 3. The SCMHC has demonstrated internal
consistency with a Cronbach’s alpha of .84.
Latino Scale for Antidepressant Stigma (LSAS)
The LSAS [42] is a 7-item measure with stigma-related
statements pertaining to use of antidepressants (sample
item: “Prescription medicines for depression are for
people who are not strong”). Respondents indicate
whether they agree with the statements on a 3-point
scale ranging from 0 = “No one thinks that way” to 2
= “Everyone thinks that way.” The LSAS score is calcu-
lated by taking the sum of the 7 items and total scores
range from 0–14. The LSAS has demonstrated internal
consistency with a Cronbach’s alpha of .80.
Social Distance (SD) scale
The SD [42] is a 6-item scale, which measures desire for
social distance from someone with depression or history
of depression treatment (sample item: “Would you
socially interact with a person who is or had been in
treatment for depression if this person moves next
door?”). Respondents answer no, maybe, or yes to each
item, scored as 0, 1, and 2, respectively. The SD score is
calculated by taking the sum of items 1 – 6. Total score
ranges from 0 to 12. Lower scores indicate greater social
distance. The SD has demonstrated internal consistency
with a Cronbach’s alpha of .75.
Data monitoring and analysis
The data monitoring will focus on the proper collection
of the depression measures, the depression knowledge
Table 1 DESEO study assessments and frequency of administration
Assessment Purpose Screening Baseline 2nd Session (pre or post DEI) Follow-Up
Patient Health Questionnaire (PHQ-9) Measure depressive symptoms X pre X
Depression Knowledge Measure (DKM) Evaluate symptom recognition and
treatment knowledge
X post X
Stigma Concerns About Mental Health
Care (SCMHC)
Assess stigma related barriers to
depression treatment utilization
X post X
Latino Scale for Antidepressant
Stigma (LSAS)
Assess stigma related to the use
of antidepressants
X post X
Social Distance (SD) Measures desire for social distance
from someone with depression
X post X
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measure, the stigma measures and patient outcomes
after the DEI. A Project Coordinator will be responsible
for monitoring the database and provide general support
to the Depression Educator concerning issues related to
DESEO. Such issues might include identifying problems
with implementation, support to clinical staff to insure
proper use of the iPad Depression Screening and Moni-
toring application, and facilitate the proper recording of
scores in the EHR. Other duties include maintenance
and oversight of the research database, tracking of sup-
plies of depression education materials, and ensure con-
tinued fidelity of all clinic staff to the study protocols.
A sample size of 350 would be sufficient to find a
statistically significant effect size of d = .176 (α = .05,
Power [1-β] = .95). While the study is expected to
produce a far greater effect size, a large sample size will
provide additional analytic and investigative opportun-
ities surrounding the psychometric properties and
validity of the measures. The stigma measures, in par-
ticular, have not been tested in a primary care popula-
tion and are of interest in identifying barriers to mental
health treatment for Hispanic populations.
The primary analysis will assess changes in knowledge
of depression pre-DEI, post-DEI and one month post-
DEI using the Depression Knowledge Measure and
changes in cultural attitudes toward depression pre and
post DEI using the stigma measures (Table 1). Additional
analyses will determine if the DEI leads to engagement in
depression treatment for Hispanic patients by quantifying
the number of Hispanic patients diagnosed with depres-
sion who went on to begin depression treatment after the
intervention. Further analysis will quantify which treat-
ment modality the patient with depression chose after the
DEI: pharmacotherapy, counseling, or other behavioral
intervention based on follow-up phone call one month
post intervention and/or information in the EHR.
In order to evaluate the secondary aim of feasibility of
universal screening for depression utilizing the PHQ-9
[31] via the iPad Depression Screening application, a
qualitative analysis will determine if the providers and
other clinic staff are introducing the screening with
practiced scripts and conducting warm handoffs to the
Depression Educator after screening positive for depres-
sion. Additional analyses will quantify via the iPad and
clinic records if all adult patients are being screened and
the score is being placed in the EHR.
Other analyses of interest would determine if the iPad
Depression Screening application results in changes in
primary care provider approach to the diagnosis and
treatment of depression. Such analyses would include
comparing the number of Hispanic patients with new a
depression diagnosis as a percentage of the total number
of adult Hispanics patients seen in the clinic compared
to a matched set the year prior to the study based on the
EHR (baseline data). Additionally, quantifying changes in
the number of patients with a depression diagnosis being
treated with antidepressants by a primary care provider as
a percentage of the total number of Hispanics patients
seen in the clinic compared to a matched set the year
prior to the study based on the EHR (baseline data).
Discussion
This study is unique in that it aims to examine the specific
role of patient education as an intervention to increase
engagement in depression treatment, as opposed to stud-
ies which provide patient education as a component of a
larger depression treatment intervention. It is expected
that the DEI will reduce barriers to treatment of depres-
sion for Hispanic patients by increasing knowledge of the
disorder (disease literacy), its causes, symptoms and its
role in chronic disease. Discussion of myths related to
treatment will help allay fears of engaging in treatment. By
participating in the DEI, it is expected that patients will
have time to understand treatment options, participate in
shared decision making with their provider about treat-
ment, and increase engagement in treatment of depression
which will lead to improved overall health.
While it is expected that implementation of the iPad
Depression Screening application will increase identifica-
tion of a large number of patients whose depression was
previously unrecognized and might increase the workload
of the primary care providers, with the support of the DEI,
the burden of patient education about the disease and its
treatment options will be reduced. Additionally, the recog-
nition and treatment of depression will improve the treat-
ment of comorbid chronic disease and ultimately reduce
the burden on the primary care practice.
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